Reports

Five main barriers to developing biosimilars

Home/Reports | Posted 23/07/2021

According to Dr Ash Ramzan, principal consultant at Woodley BioReg, there are five main barriers preventing biosimilars from reaching their full potential.

Position of CAEME on biological and biosimilar drugs in Argentina

Home/Reports | Posted 02/07/2021

The pharmaceutical companies that comprise the Argentine Chamber of Medicinal Products (Cámara Argentina de Especialidades Medicinales, CAEME) consider that biosimilar medicines are necessary for the sustainability of the healthcare system and patient access to effective treatment.

A few drugs account for most of Medicare Part B spending

Home/Reports | Posted 25/06/2021

Findings from an analysis carried out by KFF of Medicare* spending in 2019 found that most of the Medicare Part B** spending on drugs was on a relatively small number of drugs [1]. KFF is a non-profit organization that provides independent information on national health issues.

A broader and stronger generic drug market is promoted in Mexico

Home/Reports | Posted 21/06/2021

During a press conference held on 14 November 2020, ‘A new generic medicines market’ strategy was revealed, with which ’the Health and Economic Secretaries will strengthen the companies producing generic medicines, through the linking mechanisms and technological tools, based on the principles of innovation, transparency, competitiveness and legality’ fostering firmly a wider and solid generic medicines market, for the benefit of Mexican nationals. 

A few drugs account for most of Medicare Part D spending

Home/Reports | Posted 11/06/2021

An analysis of Medicare* spending in 2019 was recently carried out by KFF, a non-profit organization that provides independent information on national health issues. The analysis found that most of the Medicare Part D** spending on drugs was on a relatively small number of drugs with only one manufacturer and without generic or biosimilar competitors [1].

A small number of drugs account for most of Medicare spending

Home/Reports | Posted 04/06/2021

A new analysis carried out by KFF, a non-profit organization that provides independent information on national health issues, has found that a relatively small share of drugs without generic or biosimilar competitors, accounted for a disproportionate share of prescription drug spending in the US Medicare* system in 2019 [1].

Rheumatologists are prescribing more biosimilars

Home/Reports | Posted 31/05/2021

Although the use of biosimilars for the treatment of autoimmune diseases varies widely by geographical region, the trend is that rheumatologists are prescribing more biosimilars.

US biosimilars pipeline for growth hormone, infertility and bone health drugs – 2021

Home/Reports | Posted 31/05/2021

Global spending on medicine continues to grow. As of 2019, approximately US$1.25 trillion had been spent on medicines, up from just US$887 billion in 2010. That number is expected to increase to US$1.59 billion by 2024, with biologicals making up an increasing part of this total due to their use to treat previously intractable diseases. In fact, spending on biologicals has doubled since 2007 and growth has outstripped that of total sales of pharmaceuticals by a significant margin. The global biologicals market in 2020 was worth approximately US$239.2 billion, and in 2020 five of the top 10 best-selling drugs were biologicals compared with a high of seven in 2018, and only three in 2008 [1].

US biosimilars pipeline for immunosuppressants, insulin and ophthalmology – 2021

Home/Reports | Posted 21/05/2021

Biologicals are becoming increasingly important in the pharmaceuticals market due to their use to treat chronic diseases. The global biologicals market in 2020 was worth approximately US$239.2 billion, and in 2020 five of the top 10 best-selling drugs were biologicals compared with a high of seven in 2018, and only three in 2008 [1].

US biosimilars pipeline for supportive care, oncology and TNF inhibitors – 2021

Home/Reports | Posted 14/05/2021

Biologicals represent many of the most promising new therapies for previously intractable diseases and are becoming increasingly important in the pharmaceuticals market. The global biologicals market in 2020 was worth approximately US$239.2 billion, and in 2020 five of the top 10 best-selling drugs were biologicals compared with a high of seven in 2018, and only three in 2008 [1].